Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase...

por Zinzani, Pier Luigi, Khuageva, Nuriet K, Wang, Huaqing, Garicochea, Bernardo, Walewski, Jan, Van Hoof, Achiel, Soubeyran, Pierre, Caballero, Dolores, Buckstein, Rena, Esseltine, Dixie-Lee, Theocharous, Panteli, Enny, Christopher, Zhu, Eugene, Elsayed, Yusri A, Coiffier, Bertrand
Publicado 2012